NEVVI Medicare utilization intelligence

← back

MOSALPURIA, KAILASHM.D., MPH NPI 1669636643 Clinician

Medical Oncology · LINCOLN, NE

Specialty Medical Oncology — from billed Medicare claims
In practice about 21 years since medical school (class of 2005, self-reported to CMS)
Location LINCOLN, NE · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 88 codes billed · 240,004 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
NEBRASKA HEMATOLOGY-ONCOLOGY PC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2023-05

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9271 Injection, pembrolizumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9299 Injection, nivolumab, 1 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J0897 Injection, denosumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J0461 Injection, atropine sulfate, 0.01 mg
J2469 Injection, palonosetron hcl, 25 mcg
J2796 Injection, romiplostim, 10 micrograms
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
80053 Blood test, comprehensive group of blood chemicals
J0640 Injection, leucovorin calcium, per 50 mg
36415 Insertion of needle into vein for collection of blood sample
83615 Lactate dehydrogenase (enzyme) level
96375 Injection of additional new drug or substance into vein
J9190 Injection, fluorouracil, 500 mg
J9206 Injection, irinotecan, 20 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
Q5130 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
96372 Injection of drug or substance under skin or into muscle
J9395 Injection, fulvestrant, 25 mg
96413 Administration of chemotherapy into vein, 1 hour or less
82728 Ferritin (blood protein) level
J3480 Injection, potassium chloride, per 2 meq
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J9045 Injection, carboplatin, 50 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J7030 Infusion, normal saline solution , 1000 cc
82607 Cyanocobalamin (vitamin b-12) level
82378 Carcinoembryonic antigen (cea) protein level
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J9060 Injection, cisplatin, powder or solution, 10 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
84443 Blood test, thyroid stimulating hormone (tsh)
96415 Administration of chemotherapy into vein, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
82550 Creatine kinase (cardiac enzyme) level, total
96360 Infusion into a vein for hydration, 31-60 minutes
80048 Blood test, basic group of blood chemicals (calcium, total)
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
82150 Amylase (enzyme) level
83690 Lipase (fat enzyme) level
83735 Magnesium level
J3475 Injection, magnesium sulfate, per 500 mg
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
82533 Cortisol (hormone) measurement, total
96416 Administration of prolonged chemotherapy into vein
J1200 Injection, diphenhydramine hcl, up to 50 mg
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
84439 Thyroxine (thyroid chemical), free
J3490 Unclassified drugs
82306 Vitamin d-3 level
84238 Chemical receptor analysis
82746 Folic acid level, serum
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
85045 Red blood count, automated test
84550 Uric acid level, blood
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
84153 Psa (prostate specific antigen) measurement, total
96411 Administration of additional new drug or substance into vein using push technique
36591 Collection of blood sample from implanted device
96374 Injection of drug or substance into vein
G0023 Principal illness navigation services by certified or trained auxiliary personnel under the direction of a physician or other practitioner, including a patient navigator; 60 minutes per calendar month, in the following activities: person-centered assessmen
G0024 Principal illness navigation services, additional 30 minutes per calendar month (list separately in addition to g0023)
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
85610 Blood test, clotting time
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
99221 Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
82668 Erythropoietin (protein) level
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
81000 Manual urinalysis test with examination using microscope, non-automated

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.